Type of Posting: Notice of Intent to Revise
Posting Date: 12–Feb–2024
Targeted Official Date: 1–Aug–2024
Expert Committee: Various
In accordance with the Rules and Procedures of the Council of Experts, this is to provide notice that USP intends to revise the Chemical Information of select standards in accordance with the General Announcement published on March 25, 2022.
USP published Chemical Information updates on February 1, 2024. The updated standards will be official on August 1, 2024. The changes will be highlighted in yellow and followed by the notation (CN 1-Aug-2024) in the updated standards.
The impacted standards are as follows:
- Articaine Hydrochloride (USP Monograph)
- Azithromycin Tablets (USP Monograph)
- Cefpodoxime Proxetil (USP Monograph)
- Chloroprocaine Hydrochloride (USP Monograph)
- Dutasteride (USP Monograph)
- Everolimus (USP Monograph)
- Flecainide Acetate (USP Monograph)
- Flecainide Acetate Tablets (USP Monograph)
- Gadoteridol (USP Monograph)
- Glyceryl Distearate (NF Monograph)
- Oseltamivir Phosphate Capsules (USP Monograph)
- Rotigotine (USP Monograph)
- Rotigotine Transdermal System (USP Monograph)
- Sotalol Hydrochloride (USP Monograph)
- Sotalol Hydrochloride Tablets (USP Monograph)
- Tranexamic Acid (USP Monograph)
- Tranexamic Acid Injection (USP Monograph)
- Tranexamic Acid Tablets (USP Monograph)
- Trimipramine Maleate (USP Monograph)
Should you have any questions, please contact Elena Gonikberg, Sr. Principal Scientist (eg@usp.org).